Kathrine Gamborg Andreassen (1966)
Kathrine Gamborg Andreassen was elected Chair of the Board June 2018. Kathrine is an experienced marketing professional and has held various executive positions in Consumer Health and FmCG (Orkla, Kemetyl). She held the position as the Chief Executive Officer at Weifa ASA until the company was acquired by Karo Pharma AB November 2017, and prior to that VP Consumer Health at Weifa AS. She has several years of experience as a consultant in strategy, marketing research and M&A. She is also co-owner and the Chair of the Board at Novicus Pharma AS. Gamborg Andreassen studied Business Administration (BBA) at Handelsakademiet/ Oslo Business School and holds a MSc in Business Strategy & Marketing from the University of Wisconsin, Madison.
Rikard Storvestre (1959)
Rikard Storvestre holds a Master of Science from the University of Trondheim as well as a B.A. of Business Administration from BI in Oslo. Storvestre is an entrepreneur and investor and has started more than 10 companies in different industries. Several of these companies are currently owned by Pfizer and a number of different private equity funds. Storvestre has been an active investor on the Oslo Stock Exchange for more than 30 years and has ownership interests in a number of companies. In Navamedic he controls 30% of the share capital, privately and through his holding company, Nobelsystem Scandinavia AS. Rikard Storvestre is a Norwegian citizen, but lives in Brazil for longer periods through the year.
Jostein Davidsen (1959)
Jostein Davidsen has been a board member in Navamedic since January 2017.Jostein brings more than 30 years of experience from the international pharmaceuticals industry, most recently serving as the Chief Executive Officer of the Acino Pharmaceuticals in Switzerland.
He previous founded NYCOMED Russia – CIS, that become one of the top leaders on the Russian - CIS pharmaceutical markets, which grew to over 1500 employees including local manufacturing in 2011 before Nycomed Pharma was acquired by Takeda Pharmaceuticals.
He served after the transaction as a Corporate Officer and the Head of the Emerging Markets at Takeda Pharmaceuticals International based in Zurich Switzerland. He was during this time named the world’s second most influential pharma-industry leader in Emerging Markets by Scrip (the pharmaceutical international news journal).
Davidsen studied Business and Administration at Handelsakademiet in Oslo and have completed several Executive Management Programs and Board learning program at IMD, Lausanne Switzerland.
Svein Erik Nicolaysen (1963)
Svein Erik Nicolaysen was elected Director of Navamedic in August 2009. He is an authorised accountant with accounting practice from Arthur Andersen and Vesterålen-Revisjon AS. From 1998 through 2008, Mr. Nicolaysen held the position as the Chief Executive Officer of the company Vesterålen Naturprodukter AS and Nordic Sales Group AS, companies specialising in direct sales and marketing of health care products such as Omega 3 concentrates. After these companies were sold to Ferrosan AS (DK), Mr Nicolaysen was a member of the Management Board in Ferrosan AS until the end of 2008. From 2009 to 2015 he held the position as the Chief Executive Officer of Intersys AS, now Nobelsystem Scandinavia, the largest shareholder in Navamedic. Since 2015 Mr Nicolaysen has run his own consulting company and has several directorships. He holds 50.000 shares in the Company.